Healthcare
Stratec SE(STSEY)
Live Price
Offline$5.51
+0.00% today
1Y Change
-17.76%
Window
Jun 23, 2025 โ Jun 15, 2026
- Market Cap
- $210.00M
- Revenue Growth
- -1.6%
- EPS Growth
- -75.7%
- Dividend Yield
- 3.4%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stratec SE (STSEY) is a Healthcare stock with a market cap of $210.00M and listed on OTC. The stock last traded around $5.51 and down 17.8% across the available one-year price window (Jun 23, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of -1.6%, EPS growth of -75.7%, a dividend yield of 3.4%. What stands out right now is revenue -1.6%, EPS -75.7%, free cash flow +1425.4% with operating margin 3.9% and ROIC -0.1%. The dividend matters to the case here, with a current yield around 3.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines STSEY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.6% vs +7.6% peer median
Operating Margin
Below sector median
+3.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Nov 7, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.6% and EPS is at -75.7%, with operating margin around 3.9%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.4%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Nov 7, 2025 | โ | +0.0% | +2.0% | +2.0% |
2025 May 30, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 19, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STSEY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
STSEY Max Drawdown
-25.37%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for STSEY and SPY.
Company Overview
Stratec SE
Other OTC
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
- Leadership
- Marcus Wolfinger
- IPO Date
- May 13, 2020
- Employees
- 1.5k
- Street Address
- Gewerbestrasse 37
- Mailing
- Birkenfeld, 75217
- Region
- Birkenfeld, DE
- Reporting Currency
- USD
- Investor Line
- 49 7082 7916 0
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 9.6
- Price/Sales
- 0.9
- Price/Book
- 0.9
Growth
- Revenue
- -1.6%
- EPS
- -75.7%
- Free Cash Flow
- +1425.4%
Profitability
- Gross Margin
- 25.6%
- Operating Margin
- 3.9%
- Net Margin
- -0.1%
- ROE
- -0.1%
- ROIC
- -0.1%
Balance Sheet
- Debt/Equity
- 0.56
- Current Ratio
- 3.97
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.